Clinical Trial Update: Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of the RRG001 gene therapy in subjects with neovascular age-related macular degeneration is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RRG001 (RRG001 gene therapy)

Snippet

Sponsor: Shanghai Refreshgene Technology Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: RECRUITING